menu
    • menu
    [{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaEssentia \/ Axis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEssentia \/ Axis Therapeutics"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"JAK2V617F","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution For Injection In Pre-Filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"JAK2V617F","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution For Injection In Pre-Filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"JAK1","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0.46000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.46000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"3","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Not Applicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Pint Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Pint Pharma","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEssentia \/ Pint Pharma"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Myeloid Immune Checkpoint Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"2","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by PharmaEssentia

    Menu

    PharmaEssentia

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaEssentia Completes Enrollment for Phase 2b and Phase 3 Trials in Blood Disorders

                            Details : BESREMi (ropeginterferon alfa-2b-njft) targets IFNAR to initiate downstream signaling through the activation of JAK1 and TYK2 and STAT proteins. It is being investigated for essential thrombocythemia.

                            Brand Name : Besremi

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 25, 2024

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Myeloid Immune Checkpoint Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : WuXi Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            PharmaEssentia Enters into Exclusive Global License Agreement with WuXi Biologics for a Myeloid Immune Checkpo...

                            Details : Under the agreement, PharmaEssentia will obtain the global exclusive rights to research, develop, manufacture and commercialize a myeloid immune checkpoint antibody candidate.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 03, 2023

                            Lead Product(s) : Myeloid Immune Checkpoint Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : WuXi Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Pint Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin...

                            Details : Under the agreement, Pint-Pharma will be obtaining and maintaining all marketing authorizations and commercializing BESREMi (ropeginterferon alfa-2b-njft), the first approved mono-pegylated proline interferon for polycythemia vera, a rare blood cancer, i...

                            Brand Name : Besremi

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 02, 2023

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Pint Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as...

                            Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins. It is indicated for the polycythemia vera.

                            Brand Name : BESREMi

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 23, 2023

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Nona Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center

                            Details : The collaboration will leverage Nona’s proprietary Harbour Mice® fully human antibody transgenic mice platform for the discovery of fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb)...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 12, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Nona Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaEssentia Initiates Phase 3b Trial of Ropeginterferon alfa-2b-njft Investigatng New Dosing Regimen for Pa...

                            Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins. It is being investigated for polycythemia vera.

                            Brand Name : BESREMi

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 03, 2023

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Undisclosed

                            Deal Size : $462.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            PharmaEssentia Corporation Announces Closing of Global Depositary Receipt Offering, Generating US$462.7M to Su...

                            Details : The net proceeds from the offering will be used to to support growth plans and pipeline development, including Besremi (ropeginterferon alfa-2b-njft), an innovative monopegylated, long-acting interferon for the treatment of polycythemia vera (PV) in adul...

                            Brand Name : Besremi

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 21, 2023

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Undisclosed

                            Deal Size : $462.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaEssentia Initiates Phase 2b Trial of Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) in ...

                            Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins.

                            Brand Name : BESREMi

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 23, 2023

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinical Review of Ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outc...

                            Details : BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins.

                            Brand Name : BESREMi

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 02, 2023

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            PharmaEssentia

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Jo...

                            Details : BESREMi (ropeginterferon alfa-2b-njft), is an innovative monopegylated, long-acting interferon. With its unique pegylation technology, BESREMi has a long duration of activity in the body and is aimed to be administered once every two weeks.

                            Brand Name : Besremi

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 12, 2022

                            Lead Product(s) : Ropeginterferon-Alfa-2b

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth